Bounty of New HCC Therapies Spurs Need for More Research

Christin Melton, ELS
Published: Friday, May 10, 2019
Dr Ghassan Abou-Alfa

Ghassan Abou-Alfa, MD
The rapid expansion of therapeutic options for patients with hepatocellular carcinoma (HCC) during the past 2 years is inspiring, but optimal integration of the new drugs into the treatment paradigm requires several key developments, according to a panel of experts. These include greater research into biomarkers that would help inform therapy choices, earlier treatment for patients diagnosed with HCC, and clinical trials that test combination strategies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication